Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

This study (called SELENA) is testing a combination of two drugs — alpelisib (a targeted PI3K inhibitor) and pembrolizumab (an immunotherapy) — in people with metastatic melanoma or triple-negative breast cancer (TNBC) that has progressed on prior treatments. **You may be eligible if...** - You are 18 or older with confirmed metastatic melanoma or triple-negative breast cancer - Your cancer has progressed on standard treatments or no standard options are available - You are willing to provide a tumor biopsy sample - You meet required blood count and organ function thresholds **You may NOT be eligible if...** - You have uncontrolled diabetes (alpelisib can raise blood sugar) - You have active autoimmune disease requiring treatment - You have severe lung or heart conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.